Dr. Robert A. Kloner to Serve on HeartLung Technologies Advisory Board
HRMI's Chief Science Officer and Director of Cardiovascular Research, Robert A. Kloner, MD, PhD, has been appointed to the advisory board for HeartLung Technologies, a national group that focuses on Preventive Cardiology and other aspects of Preventive Medicine. With his extensive experience and pioneering research in cardiovascular health, Dr. Kloner will play a key role in shaping future initiatives. His expertise will help develop cutting-edge solutions for early detection of heart disease, lung cancer, osteoporosis, fatty liver, and other fatal conditions. Dr. Kloner's 45-year career includes esteemed roles at Northwestern University, Harvard Medical School, the University of Southern California, and recently, Caltech (The California Institute of Technology). He has made significant advancements in understanding heart disease pathophysiology, treatments, and the impact of environmental factors on cardiovascular health.
HeartLung Technologies aims to help people live long by eliminating preventable deaths caused by heart attacks, lung cancer, osteoporosis, chronic pulmonary obstructive disease (COPD), fatty liver disease, and other deadly medical conditions. HeartLung’s team of industry-leading physicians and engineers are dedicated to increasing people's life-span and health-span by starting with taking out America’s most deadly killers: heart disease and lung cancer. HeartLung is innovating for the millions of Americans and many more worldwide who can benefit from early detection of preventable fatal diseases. HeartLung.AI is a portfolio company of American Heart Technologies (AHT) founded by Dr. Morteza Naghavi, a leader in preventive cardiology and health-tech, former faculty of Texas Heart Institute and University of Texas in 2007. AHT was established as a vehicle for commercialization of innovative healthcare solutions, three of which received FDA approval and were commercialized under portfolio companies Endothelix Inc., and CardioNexus Corp, and HeartLung Corp.
Click to read the full press release.